Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Solid Tumors Harboring NTRK Fusion Clear all

Completed Phase 2 Interventional

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

NCT02576431

View directory record Official record

Conditions: Solid Tumors Harboring NTRK Fusion
Interventions: BAY2757556 (Larotrectinib, Vitrakvi); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older

Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 18
States / cities: Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more

Source: ClinicalTrials.gov public record

Updated Apr 27, 2026 · Synced May 21, 2026, 5:35 PM EDT

Active, not recruiting Phase 2 Interventional Results available

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

NCT03213704

View directory record Official record

Conditions: Advanced Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Larotrectinib Sulfate, Magnetic Resonance Imaging, Radionuclide Imaging, X-Ray Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years

Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 122
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 95 more

Source: ClinicalTrials.gov public record

Updated Apr 22, 2026 · Synced May 21, 2026, 5:35 PM EDT

Active, not recruiting Phase 1Phase 2 Interventional

A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

NCT02637687

View directory record Official record

Conditions: Solid Tumors Harboring NTRK Fusion
Interventions: Larotrectinib (Vitrakvi, BAY2757556); Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 21 Years

Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 11
States / cities: Los Angeles, California • Palo Alto, California • Orlando, Florida + 7 more

Source: ClinicalTrials.gov public record

Updated Jun 21, 2025 · Synced May 21, 2026, 5:35 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants

NCT04771390

View directory record Official record

Conditions: Solid Tumors Harboring NTRK Fusion
Interventions: Selitrectinib (BAY2731954) Adult tablet, Selitrectinib (BAY2731954) Pediatric tablet, Selitrectinib (BAY2731954) Oral solution, Selitrectinib (BAY2731954) Oral suspension; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Source: ClinicalTrials.gov public record

Updated Aug 24, 2021 · Synced May 21, 2026, 5:35 PM EDT

Completed Phase 1 Interventional

A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

NCT03215511

View directory record Official record

Conditions: Solid Tumors Harboring NTRK Fusion
Interventions: Selitrectinib (BAY2731954); Drug
Lead sponsor: Bayer; Industry
Eligibility: 1 Month and older

Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 17
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 13 more

Source: ClinicalTrials.gov public record

Updated Oct 29, 2024 · Synced May 21, 2026, 5:35 PM EDT

Recruiting No phase listed Observational

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

NCT04142437

View directory record Official record

Conditions: Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Interventions: larotrectinib(Vitrakvi, BAY2757556); Drug
Lead sponsor: Bayer; Industry
Eligibility: Not listed

Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 51
States / cities: Mesa, Arizona • Los Angeles, California • Newport Beach, California + 42 more

Source: ClinicalTrials.gov public record

Updated Apr 13, 2026 · Synced May 21, 2026, 5:35 PM EDT

Active, not recruiting Phase 2 Interventional

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT02568267

View directory record Official record

Conditions: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor
Interventions: Entrectinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older

Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 53
States / cities: Phoenix, Arizona • Duarte, California • La Jolla, California + 36 more

Source: ClinicalTrials.gov public record

Updated Mar 5, 2026 · Synced May 21, 2026, 5:35 PM EDT

Completed No phase listed Observational

A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice

NCT05192642

View directory record Official record

Conditions: Solid Tumors Harboring NTRK Fusion
Interventions: Larotrectinib(Vitrakvi, BAY2757556), Data on other treatments; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older

Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Whippany, New Jersey

Source: ClinicalTrials.gov public record

Updated Nov 13, 2023 · Synced May 21, 2026, 5:35 PM EDT

Completed Phase 1 Interventional

A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

NCT02122913

View directory record Official record

Conditions: Solid Tumors Harboring NTRK Fusion
Interventions: Larotrectinib (Vitrakvi, BAY2757556); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older

Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 8
States / cities: Aurora, Colorado • Boston, Massachusetts • Cleveland, Ohio + 5 more

Source: ClinicalTrials.gov public record

Updated Feb 4, 2026 · Synced May 21, 2026, 5:35 PM EDT

Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

NCT06010342

View directory record Official record

Conditions: Solid Tumor
Interventions: TL118 Capsule; Drug
Lead sponsor: Teligene US; Industry
Eligibility: 18 Years and older

Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 3
States / cities: Glendale, California • Dallas, Texas • Houston, Texas

Source: ClinicalTrials.gov public record

Updated Apr 27, 2026 · Synced May 21, 2026, 5:35 PM EDT